Condition

Non-Hodgkin Lymphoma clinical trials and research

• 97Clinical trials
• 16NIH research projects
• 34Countries

Newest Non-Hodgkin Lymphoma clinical trials

All recruiting trials (97)

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• XNW5004 with CHOP/CHOEP in Untreated Peripheral T-Cell Lymphoma

  This study tests XNW5004 together with CHOP or CHOEP in adults with newly diagnosed peripheral T-cell lymphoma to see if the combination is safe and active.

  Recruiting Phase 1/2 Evopoint Biosciences Inc. · Shanghai, Shanghai Municipality · NCT07730515

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• JLM019 Injection in Adults with Advanced Cancers

  This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07623850

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• In‑body CAR‑T generation with PIC1 injection for relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  This will try a single intravenous PIC1 injection to create CAR‑T cells inside the body for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT07456371

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging

  Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT07292272

• LV009 injection for relapsed or refractory CD19-positive blood and lymph cancers

  This will test whether LV009 injections are safe for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma or acute lymphoblastic leukemia.

  Recruiting Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Suzhou, Jiangsu · NCT07284927

• Ruxolitinib plus pembrolizumab for relapsed or refractory Hodgkin and non-Hodgkin lymphomas

  This trial will try adding ruxolitinib to pembrolizumab to see if it is safe and helps people whose Hodgkin or non-Hodgkin lymphomas have come back or did not respond to prior treatment.

  Recruiting Phase 2 Columbia University · New York, New York · NCT07283822

• KSV01 injection for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test a new injectable treatment called KSV01 in adults with relapsed or refractory diffuse large B‑cell lymphoma to see if it is safe and can help control the cancer.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Wuhan, Hubei · NCT07260812

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Voice monitoring for side effects during CAR T-cell therapy

  This project will test whether twice-daily smartphone voice recordings and brief daily neurologic checks can spot early neurologic side effects in adults receiving FDA-approved CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07249528

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• SB-4826 for adults with advanced solid tumors or non-Hodgkin lymphoma

  This trial tests whether the oral drug SB-4826, given alone or with rituximab, is safe and can help adults with advanced solid tumors or non-Hodgkin lymphoma.

  Recruiting Phase 1/2 University of California, San Diego · La Jolla, California · NCT07222631

• Linperlisib plus CPT (cyclophosphamide, prednisone, thalidomide) for relapsed or refractory non-Hodgkin lymphoma

  This trial tests whether adding linperlisib to a CPT regimen helps adults with relapsed or refractory non-Hodgkin lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07195799

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Mozobil (plerixafor) to mobilize stem cells for autologous transplant

  This trial will test whether starting with G‑CSF and giving Plerixafor only when needed can collect enough stem cells for adults with multiple myeloma or lymphoma undergoing autologous transplant while possibly lowering engraftment syndrome.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07188090

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Ciprofloxacin versus ceftazidime for high-risk neutropenic fever in children with blood cancers

  We will test whether ceftazidime or ciprofloxacin works better as the first antibiotic for children (0–18) with blood cancers who develop high-risk fever from low neutrophil counts.

  Recruiting Phase 4 Gadjah Mada University · Sleman, DI Yogyakarta · NCT07016165

• Carmustine treatment for lymphoma patients

  This study is testing if adding a new drug called VI-0609 to a standard treatment helps lymphoma patients do better after a stem cell transplant.

  Recruiting at 4 sites Phase 2 Vivus LLC · Goodyear, Arizona and 3 other locations · NCT06915246

• Long-term pirtobrutinib continuation for people with previously treated CLL/SLL or non-Hodgkin lymphoma

  People who are already taking pirtobrutinib in an earlier trial can continue the drug or their follow-up visits so doctors can see if it stays safe and keeps helping over the long term.

  Recruiting at 25 sites Phase 4 Eli Lilly and Company · Miami, Florida and 35 other locations · NCT06876662

• Long-term safety follow-up of pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma

  This program lets people who previously received pirtobrutinib in a Lilly study continue treatment or follow-up so doctors can see if the drug remains safe over the long term.

  Recruiting at 32 sites Phase 4 Eli Lilly and Company · Jacksonville, Florida and 37 other locations · NCT06876649

• GB5005 CART-cell injection for treating relapsed B-cell non-Hodgkin lymphoma

  This study is testing a new CAR-T cell treatment called GB5005 to see if it can help people with relapsed B-cell non-Hodgkin lymphoma feel better and manage side effects.

  Recruiting Phase 1 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06875063

• Evaluating the risk of blood cancers in firefighters

  This study is testing if firefighters who have been exposed to harmful substances are at a higher risk for blood cancers and related conditions.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT06870760

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using IOMAB-ACT and CAR-T cell therapy

  This study is testing a new treatment combining a special radioactive drug and CAR-T cell therapy to see if it helps people with relapsed or hard-to-treat diffuse large B-cell lymphoma.

  Recruiting Phase 1/2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06768905

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Imaging study using 64Cu-GRIP B in patients with non-Hodgkin lymphoma receiving CAR-T therapy

  This study is testing a new imaging method to see if it can help track how well CAR-T therapy is working in patients with relapsed or hard-to-treat non-Hodgkin lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06522932

• Vitamin A and D supplementation for patients undergoing allogeneic hematopoietic transplantation

  This study is testing if giving high doses of vitamins A and D before a stem cell transplant can help patients with certain blood cancers have fewer complications like infections and graft-versus-host disease.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06508099

• Testing AXT-1003 for advanced malignant tumors

  This study is testing a new treatment called AXT-1003 to see if it is safe and effective for people with advanced cancers like non-Hodgkin lymphoma and solid tumors.

  Recruiting at 5 sites Phase 1 Axter Therapeutics (Beijing) Co., Ltd · Beijing and 4 other locations · NCT06484985

• CAR T cell therapy for relapsed large B-cell lymphoma

  This study is testing a new CAR T cell therapy to see if it can help adults with relapsed large B-cell lymphoma who haven't responded to previous treatments.

  Recruiting Phase 2 Shanghai Ming Ju Biotechnology Co., Ltd. · Tianjin, Tianjin Municipality · NCT06479356

• Preventing cytokine release syndrome with siltuximab before epcoritamab treatment

  This study is testing if giving siltuximab before treatment with epcoritamab can help prevent serious side effects in people with large B-cell lymphoma or follicular lymphoma.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06447376

• Examining the effects of cannabis use in cancer patients undergoing treatment

  This study is trying to see how using cannabis affects newly diagnosed cancer patients who are starting treatment for their illness.

  Recruiting at 491 sites Wake Forest University Health Sciences · Fairbanks, Alaska and 490 other locations · NCT06418204

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Using Wisconsin ginseng to reduce cancer-related fatigue

  This study is testing if Wisconsin ginseng can help reduce fatigue in cancer patients compared to a placebo over eight weeks.

  Recruiting at 14 sites Phase 3 Mayo Clinic · Albert Lea, Minnesota and 14 other locations · NCT06395441

• Change in how kids and young adults with Hodgkin or non-Hodgkin lymphoma process medicines

  This study will test whether giving small probe medicines can show changes in how children and young adults (ages 6–25) with Hodgkin or non-Hodgkin lymphoma metabolize drugs during their cancer treatment.

  Recruiting Phase 1 Murdoch Childrens Research Institute · Melbourne, Victoria · NCT06383338

• Testing tumor samples from patients with second cancers after gene therapy

  This study is testing tumor samples from patients who have had gene therapy to see if there's a link between the treatment and the development of a second cancer.

  Recruiting at 5 sites Bristol-Myers Squibb · Portland, Oregon and 7 other locations · NCT06357754

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• Gene knock-out CAR-T cell therapy for B cell lymphoma

  This study is testing a new CAR-T cell therapy for people with hard-to-treat B cell lymphoma to see if it is safe and effective.

  Recruiting at 3 sites Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06323525

• Using post-transplant cyclophosphamide and ATG for blood cancer transplants

  This study is testing whether using post-transplant cyclophosphamide and ATG can help prevent graft-versus-host disease in patients with blood cancers who are getting stem cell transplants.

  Recruiting Phase 1/2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT06299462

• Testing GLB-002 for patients with relapsed or refractory Non-Hodgkin Lymphomas

  This study is testing a new treatment called GLB-002 to see if it can help people with Non-Hodgkin lymphoma who haven't had success with other therapies.

  Recruiting at 13 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 12 other locations · NCT06219356

• Evaluating TGRX-814 in patients with blood cancers

  This study is testing a new drug called TGRX-814 to see if it is safe and effective for people with blood cancers like lymphoma and leukemia.

  Recruiting Phase 1/2 Shenzhen TargetRx Co., Ltd. · Tianjin, Tianjin Municipality · NCT06206174

• Understanding the causes and outcomes of lymphoma in Chinese patients

  This study looks at the clinical and genetic details of lymphoma patients in China to see how these factors affect the disease and its outcomes.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06203652

• Treatment for relapsed B-cell lymphoma using CAR-T cells

  This study is testing a new CAR-T cell therapy to see if it can help people with relapsed B-cell lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Beijing, Beijing Municipality · NCT06180174

• Banked C7R-modified allogeneic CD30-targeted CAR T cells for CD30-positive lymphomas

  This will try a donated (banked) C7R.CD30.CAR-EBVST cell infusion to treat people aged 12–75 whose CD30-positive lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT06176690

• Evaluating AZD3470 for relapsed or refractory blood cancers

  This study is testing a new drug called AZD3470 to see if it can help people with hard-to-treat blood cancers feel better and respond to treatment.

  Recruiting at 28 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT06137144

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• Long-term follow-up for patients treated with zamtocabtagene autoleucel

  This study follows patients who have received a specific CAR T-cell therapy for non-Hodgkin lymphoma to see how they do over time and if there are any long-term side effects.

  Recruiting at 10 sites Miltenyi Biomedicine GmbH · Gilbert, Arizona and 10 other locations · NCT06116110

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Safety evaluation of CC312 in adults with relapsed B-cell cancers

  This study is testing a new treatment called CC312 to see if it's safe for adults with relapsed B-cell cancers.

  Recruiting Phase 1 CytoCares Inc · Tianjin, Tianjin Municipality · NCT06037018

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• Peer support program to improve cancer diagnosis and treatment for young people with HIV in Zambia

  This study is testing a peer support program to help young people with HIV in Zambia get diagnosed and treated for cancer more effectively.

  Recruiting Implenomics · Lusaka · NCT06004011

• Combining Ibrutinib with standard treatment for patients with primary CNS lymphoma who can't undergo transplant

  This study is testing if combining the drug ibrutinib with standard treatments can help patients with primary CNS lymphoma who can't have a transplant live better and longer.

  Recruiting at 8 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 7 other locations · NCT05998642

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Investigating cognitive impairment in young cancer patients during and after chemotherapy

  This study is testing how chemotherapy affects memory and attention in children and young adults with cancer to better understand their cognitive challenges during and after treatment.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05840575

• Improving health for lymphoma survivors through diet and exercise

  This study tests if following a Mediterranean diet and doing home exercises can help lymphoma patients on chemotherapy finish their treatment and feel better during it.

  Recruiting University of Miami · Miami, Florida · NCT05839210

• Treatment of aggressive large B-cell lymphoma with LYL314

  This study is testing a new CAR T-cell therapy called LYL314 to see if it can effectively treat aggressive large B-cell lymphoma in different groups of patients.

  Recruiting at 35 sites Phase 1/2 Lyell Immunopharma, Inc. · Irvine, California and 34 other locations · NCT05826535

• Evaluating MT-601 for patients with relapsed or refractory lymphoma

  This study is testing a new treatment called MT-601 to see if it can help people with relapsed or hard-to-treat lymphoma feel better.

  Recruiting at 7 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 6 other locations · NCT05798897

• Evaluating XEMBIFY® with standard treatment to prevent infections in patients with certain blood cancers

  This study is testing if adding XEMBIFY® to standard treatment can help prevent serious infections in adults with certain blood cancers.

  Recruiting at 56 sites Phase 3 Grifols Therapeutics LLC · Bullhead City, Arizona and 61 other locations · NCT05645107

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Combination treatment for patients with primary central nervous system lymphoma

  This study is testing a new combination of treatments for adults with primary central nervous system lymphoma who can't have high-dose chemotherapy to see if it helps them get better and live longer.

  Recruiting Phase 2 University of Cologne · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT05583071

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Combining pirtobrutinib and venetoclax for treating relapsed mantle cell lymphoma

  This study is testing if combining two medications, pirtobrutinib and venetoclax, can help people with relapsed mantle cell lymphoma feel better and improve their chances of survival.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05529069

• Investigating SCR-6920 Capsule for Patients with Advanced Malignant Tumors

  This study is testing a new capsule called SCR-6920 to see if it is safe and can help patients with advanced tumors who haven't had success with other treatments.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT05528055

• Improving communication for Spanish-speaking families with cancer

  This study is trying to improve communication and support for Spanish-speaking families dealing with leukemia or non-Hodgkin lymphoma to help them feel more included and better understand their treatment.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT05425992

• Combining Pomalidomide with Chemotherapy for HIV-Related Lymphomas

  This study is testing if adding a drug called pomalidomide to chemotherapy can help adults with HIV-related lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05389423

• Treatment for B-cell malignancies using BGB-16673

  This study is testing a new drug called BGB-16673 to see if it can safely help people with different types of B-cell cancers.

  Recruiting at 29 sites Phase 1/2 BeOne Medicines · Bengbu, Anhui and 28 other locations · NCT05294731

• Combining targeted immunotherapy with chemotherapy for pediatric lymphoma

  This study is testing if adding a new type of immunotherapy to lower doses of chemotherapy can help children and young adults with certain types of lymphoma while keeping them safe.

  Recruiting at 2 sites Phase 2 New York Medical College · Birmingham, Alabama and 2 other locations · NCT05253495

• Testing a new CAR T cell therapy for adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR T cell therapy to see if it can help adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT05098613

• Imaging of tumors using a specific PET scan agent

  This study is testing a new PET scan agent to see if it can help find and understand tumors in patients with different blood cancers and solid tumors.

  Recruiting Early Phase 1 Memorial Sloan Kettering Cancer Center · New York, New York · NCT05093335

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• KRT-232 plus acalabrutinib in relapsed/refractory DLBCL or CLL

  This trial tests a new MDM2 inhibitor (KRT-232) together with acalabrutinib to see if the combination helps adults with relapsed or refractory DLBCL or CLL.

  Recruiting at 45 sites Phase 1/2 Kartos Therapeutics, Inc. · Goshen, Indiana and 44 other locations · NCT04502394

• Injection of CTA101 UCAR-T cells for patients with relapsed or refractory CD19+ B-line blood cancers

  This study is testing if injections of a new type of immune cell therapy can help patients with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT04227015

• Stem cell transplantation for blood disorders using specific cell depletion techniques

  This study is testing a new way of using stem cell transplants for children and young adults with blood disorders to see if removing certain cells helps them recover better and improve their quality of life.

  Recruiting Phase 2 New York Medical College · Valhalla, New York · NCT04099966

• Evaluating CCS1477 for blood cancers

  This study is testing a new drug called CCS1477 to see if it can help people with certain blood cancers who haven't responded to other treatments.

  Recruiting at 34 sites Phase 1/2 CellCentric Ltd. · Atlanta, Georgia and 38 other locations · NCT04068597

• Comparing two conditioning regimens for allogeneic hematopoietic cell transplantation

  This study is testing two different treatment plans for patients with blood cancers who are getting stem cell transplants from matched donors to see which one helps them stay healthy longer.

  Recruiting at 10 sites Phase 2 University of Liege · Antwerp and 9 other locations · NCT03852407

• Evaluating the safety of azer-cel in patients with relapsed/refractory B-cell cancers

  This study is testing a new treatment called azer-cel to see if it is safe and effective for adults with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 15 sites Phase 1 Imugene Limited · Tampa, Florida and 14 other locations · NCT03666000

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of five drugs to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03223610

• Registry for patients with lymphoid cancers

  This study is collecting information from patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma to better understand their conditions and improve treatment options.

  Recruiting A.O. Ospedale Papa Giovanni XXIII · Bergamo · NCT03131531

• Auto stem cell transplant for lymphoma patients

  This study tests if a stem cell transplant after chemotherapy can help people with Hodgkin and non-Hodgkin lymphomas, including those with HIV, who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03125642

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

• Using modified T cells to treat relapsed lymphoma

  This study is testing if specially modified T cells can help people with relapsed Hodgkin's and Non-Hodgkin lymphoma fight their cancer more effectively after chemotherapy.

  Recruiting at 2 sites Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT02917083

• Transplantation with modified stem cells and Zoledronate for pediatric cancers

  This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT02508038

• Using obinutuzumab with chemotherapy for relapsed CD20+ Non-Hodgkin Lymphoma in young patients

  This study is testing if a new drug called obinutuzumab, alone or with chemotherapy, can help young patients with relapsed CD20 positive Non-Hodgkin Lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 New York Medical College · Valhalla, New York · NCT02393157

• Using modified T-cells to treat advanced B-cell cancers

  This study is testing whether modified T-cells can help patients with advanced B-cell cancers that haven't responded to other treatments by boosting their immune system to fight the cancer better.

  Recruiting at 2 sites Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT01853631

• Access and distribution of unlicensed cryopreserved cord blood units

  This study is testing how well unlicensed frozen cord blood units work for helping both kids and adults with blood cancers recover after a transplant.

  Recruiting at 113 sites Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 141 other locations · NCT01351545

NIH-funded research (16)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Novel combination therapy for non-Hodgkin lymphoma in people and dogs

  A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11473229

• Combination therapy approach for non-Hodgkin lymphoma (NHL)

  A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11402652

• Multi-antigen T cell therapy for relapsed NHL

  A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11374461

• Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma

  Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.

  NIH research Washington University · Saint Louis, United States · NIH-11241103

• AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)

  Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11235842

• New combination therapy for non-Hodgkin lymphoma

  A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11211672

• New combination treatment for diffuse large B‑cell lymphoma

  This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11180362

• MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma

  This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11164733

• New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma

  This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-11131238

• New targeted treatments for non-Hodgkin lymphoma

  This study is working on new treatments for non-Hodgkin lymphoma using advanced antibodies that could be more effective and safer, with the hope of offering better options for patients like you.

  NIH research Washington University · Saint Louis, United States · NIH-11050386

• Combining therapies to improve treatment for non-Hodgkin lymphoma

  This study is looking at a new treatment for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, to find out how to make current therapies work better, and it involves comparing cases in people and dogs to learn more about how to fight this cancer effectively.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11043487

• Targeting a key driver of Non-Hodgkin Lymphoma using artificial intelligence

  This study is using smart computer technology to find new ways to create medicines that can help people with Non-Hodgkin Lymphoma by targeting specific proteins that are hard to treat, especially those linked to a common gene mutation.

  NIH research Baylor College of Medicine · Houston, United States · NIH-10985003

• New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma

  This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-10922163

• New combination therapy for non-Hodgkin lymphoma

  This study is looking at a new treatment approach for people with diffuse large B-cell lymphoma (DLBCL), a common type of cancer, to help improve how well therapies work, especially for those with advanced cases, by learning from both human and dog cases.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10918057

• New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.

  This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-10911718

• Finding ways to identify when non-Hodgkin lymphoma comes back using electronic health records.

  This study is working on new ways to use health records to better spot when non-Hodgkin lymphoma comes back, especially for those with diffuse large B-cell lymphoma or follicular lymphoma, so that patients can get better care and monitoring.

  NIH research Univ of Massachusetts Med Sch Worcester · Worcester, United States · NIH-10424952

Related topics

Quick answers

How many Non-Hodgkin Lymphoma clinical trials are recruiting right now?

97, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 34 countries. The most sites are in United States (66 trials), China (21 trials), Australia (10 trials), France (7 trials), Italy (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 30, Phase 2: 22, Phase 1/2: 17, Phase 4: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →